Background/Aims: To investigate the inhibitory effect of green tea extract, epigallocatechin gallate (EGCG), on wild-type human leiomyoma (WT-HuLM) cells and its potential action via catechol-o-methyltransferase (COMT) activity. Methods: Cell proliferation of WT-HuLM and COMT gene-silenced HuLM (COMT-shRNA-HuLM) cells treated with 0 or 100 µM EGCG for 7 days was measured using the MTT method. Total RNA and protein were extracted from cells treated with 0 or 100 µM of EGCG for 48 h. Gene expression profiling was performed using Human Signal Transduction PathwayFinder. Proliferation cell nuclear antigen (PCNA), cyclin-dependent kinase 4 (Cdk4) and COMT protein levels were detected by Western blot analyses. COMT enzyme activity was evaluated by HPLC. Results: EGCG-treated WT-HuLM cells showed significantly decreased COMT expression (p < 0.001) and enzyme activity (p < 0.05) compared to untreated WT-HuLM cells, while COMT-shRNA-HuLM cells showed no significant change. At 100 μM of EGCG, survival of WT-HuLM cells was significantly lower (p < 0.05) compared to COMT-shRNA-HuLM cells. EGCG treatment modulated multiple signaling pathways in WT-HuLM compared to untreated control, while changes were minimal or reversed in COMT-shRNA-HuLM cells. EGCG significantly decreased PCNA, Cdk4 and soluble COMT protein levels (p < 0.001) in WT-HuLM, but not in COMT-shRNA-HuLM cells. Conclusions: The antiproliferative and gene-modulating effects of EGCG on HuLM cells are mediated, at least partially, via its effect on COMT expression and enzyme activity.

Keywords:
Epigallocatechin gallate, Green tea, Leiomyoma, Uterine fibroids, Proliferation inhibition, Catechol-o-methyltransferase
1.
Stewart EA: Uterine fibroids. Lancet 2001;357:293-298.
2.
Al-Hendy A, Salama SA: Catechol-o-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig 2006;13:136-144.
3.
Othman EE, Al-Hendy A: Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol 2008;22:589-601.
4.
Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA, Willett WC, Hunter DJ: Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997;90:967-973.
5.
Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B, Baird DD: Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 2008;105:19887-19892.
6.
Takeda T, Sakata M, Isobe A, Miyake A, Nishimoto F, Ota Y, Kamiura S, Kimura T: Relationship between metabolic syndrome and uterine leiomyomas: a case-control study. Gynecol Obstet Invest 2008;66:14-17.
7.
Csatlós É, Rigó J Jr, Laky M, Joó JG: Gene expression patterns of insulin-like growth factor 2 in human uterine fibroid tissues: a genetic study with clinical correlation. Gynecol Obstet Invest 2013;75:185-190.
8.
Olmos Grings A, Lora V, Dias Ferreira G, Simoni Brum I, von Eye Corleta H, Capp E: Protein expression of estrogen receptors α and β and aromatase in myometrium and uterine leiomyoma. Gynecol Obstet Invest 2012;73:113-117.
9.
Al-Hendy A, Salama SA: Ethnic distribution of estrogen receptor-α polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril 2006;86:686-693.
10.
Salama SA, Ho SL, Wang HQ, Tenhunen J, Tilgmann C, Al-Hendy A: Hormonal regulation of catechol-o-methyl transferase activity in women with uterine leiomyomas. Fertil Steril 2006;86:259-262.
11.
Fukuda M, Tanaka T, Kamada M, Hayashi A, Yamashita Y, Terai Y, Ohmichi M: Comparison of the perinatal outcomes after laparoscopic myomectomy versus abdominal myomectomy. Gynecol Obstet Invest 2013;76:203-208.
12.
Nair S, Rajaratnam V, Thota C, Curiel DT, Al-Hendy A: Targetting adenoviral vectors for enhanced gene therapy of uterine leiomyoma. Hum Reprod 2013;28:2398-2406.
13.
Hassan M, Zhang D, Salama S, Hamada F, Arafa H, Fouad H, Walker C, Al-Hendy A: Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest 2009;68:19-32.
14.
Lin JK, Liang YC, Lin-Shiau SY: Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol 1999;58:911-915.
15.
Beltz LA, Bayer DK, Moss AL, Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006;6:389-406.
16.
Friedman M: Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res 2007;51:116-134.
17.
Mukhtar H, Ahmad N: Green tea in chemoprevention of cancer. Toxicol Sci 1999;52:111-117.
18.
Gupta S, Hussain T, Mukhtar H: Molecular pathway for (-)- epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys 2003;410:177-185.
19.
Chen C, Yu R, Owuor ED, Kong AN: Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 2000;23:605-612.
20.
Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst (Bethesda) 1997;89:1881-1886.
21.
Gupta S, Ahmad N, Nieminen AL, Mukhtar H: Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000;164:82-90.
22.
Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME: Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol 2007;31:705-711.
23.
Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS: Inhibition of human liver catechol-o-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 2005;69:1523-1531.
24.
Nagai M, Conney AH, Zhu BT: Strong inhibitory effects of common tea catechins and bioflavonoids on the o-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-o-methyltransferase. Drug Metab Dispos 2004;32:497-504.
25.
Lu H, Meng X, Yang CS: Enzymology of methylation of tea catechins and inhibition of catechol-o-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 2003;31:572-579.
26.
Shixian Q, VanCrey B, Shi J, Kakuda Y, Jiang Y: Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-o-methyltransferase. J Med Food 2006;9:451-458.
27.
Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Rajaratnam V, Al-Hendy A: Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril 2010;94:1887-1893.
28.
Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, Khurana A, Al-Hendy A: Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010;202:289.e1-e9.
29.
Salama AS, Kamel M, Awad M, Nasser A-HB, Al-Hendy A, Botting S, Arrastia C: Catecholestrogens induce oxidative stress and malignant transformation in endometrial glandular cells: protective effect of catechol-o-methyltransferase. Int J Cancer 2008;123:1246-1254.
30.
Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A: Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-o-methyltransferase. Fertil Steril 2011;95:247-253.
31.
Azab SS, Salama SA, Abdel-Naim AB, Khalifa AE, El-Demerdash E, Al-Hendy A: 2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells? Breast Cancer Res Treat 2009;113:9-19.
32.
Salama SA, Nasr AB, Dubey RK, Al-Hendy A: Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig 2006;13:542-550.
33.
Shen X, Puthran N, Weissman A: A refined HPLC method to measure catecholamine-o-methyltransferase activity in selected brain regions. J Neurosci Methods 2005;144:137-142.
34.
Chacko SM, Thambi PT, Kuttan R, Nishigaki I: Beneficial effects of green tea: a literature review. Chin Med 2010;5:13.
35.
Chan EW, Soh EY, Tie PP, Law YP: Antioxidant and antibacterial properties of green, black, and herbal teas of Camellia sinensis. Pharmacognosy Res 2012;3:266-272.
36.
Takada M, Nakamura Y, Koizumi T, Toyama H, Kamigaki T, Suzuki Y, Takeyama Y, Kuroda Y: Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas 2002;25:45-48.
37.
Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, Shimazu T, Willett WC, Tsugane S: Green tea drinking and subsequent risk of breast cancer in a population to based cohort of Japanese women. Breast Cancer Res 2010;12:R88.
38.
Yamabe N, Kang KS, Hur JM, Yokozawa T: Matcha, a powdered green tea, ameliorates the progression of renal and hepatic damage in type 2 diabetic OLETF rats. J Med Food 2009;12:714-721.
39.
Kang MY, Park YH, Kim BS, Seo SY, Jeong BC, Kim J-I, Kim H-H: Preventive effects of green tea (Camellia sinensis var. assamica) on diabetic nephropathy. Yonsei Med J 2012;53:138-144.
40.
Rhosdy E, Rajaratnam V, Maitra S, Sabry M, Ait Allah AS, Al-Hendy A: Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health 2013;5:477-486.
41.
Grossman MH, Emanuel BS, Budarf ML: Chromosomal mapping of the human catechol-o-methyltransferase gene to 22q11.1-q11.2. Genomics 1992;12:822-825.
42.
Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I: Genomic organization of the human catechol-o-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994;223:1049-1059.
43.
Lundstrom K, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Ulmanen I: Cloning, expression and structure of catechol-o-methyltransferase. Biochim Biophys Acta 1995;1251:1-10.
44.
Wentz MJ, Jamaluddin M, Garfield RE, Al-Hendy A: Regulation of catechol-o-methyltransferase expression in human myometrial cells. Obstet Gynecol 2006;108:1439-1447.
45.
Salama SA, Ho SL, Wang HQ, Tenhunen J, Tilgmann C, Al-Hendy A: Hormonal regulation of catechol-o-methyl transferase activity in women with uterine leiomyomas. Fertil Steril 2006;86:259-262.
46.
Salih SM, Salama SA, Fadl AA, Nagamani M, Al-Hendy A: Expression and cyclic variations of catechol-o-methyl transferase in human endometrial stroma. Fertil Steril 2008;90:789-797.
47.
Wentz MJ, Shi SQ, Shi L, Salama SA, Harirah HM, Fouad H, Garfield RE, Al-Hendy A: Treatment with an inhibitor of catechol-o-methyltransferase activity reduces preterm birth and impedes cervical resistance to stretch in pregnant rats. Reproduction 2007;134:831-839.
48.
Salih SM, Jamaluddin M, Salama SA, Fadl AA, Nagamani M, Al-Hendy A: Regulation of catechol-o-methyltransferase expression in granulosa cells: a potential role for follicular arrest in polycystic ovary syndrome. Fertil Steril 2008;89(suppl):1414-1421.
49.
Salih SM, Salama SA, Jamaluddin M, Fadl AA, Blok LJ, Burger CW, Nagamani M, Al-Hendy A: Progesterone-mediated regulation of catechol-o-methyl transferase expression in endometrial cancer cells. Reprod Sci 2008;15:210-220.
50.
Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al: Functional analysis of genetic variation in catechol-o-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-821.
51.
Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R: Deficiency in catechol-o-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008;453:1117-1121.
52.
Chen D, Wang CY, Lambert JD, Ai N, Welsh WJ, Yang CS: Inhibition of human liver catechol-o-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 2005;69:1523-1531.
53.
Wu AH, Tseng CC, Van Den Berg D, Yu MC: Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res 2003;63:7526-7529.
54.
Zhu BT, Shim JY, Nagai M, Bai HW: Molecular modeling study of the mechanism of high-potency inhibition of human catechol-o-methyltransferase by (-)-epigallocatechin-3-o-gallate. Xenobiotica 2008;38:130-146.
55.
Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500-2505.
56.
Yang H, Landi-Piwowar K, Chan TH, Dou QP: Green tea polyphenols as proteosome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets 2010;11:296-306.
57.
Berthet C, Kaldis P: Cdk2 and Cdk4 cooperatively control the expression of Cdc2. Cell Div 2006;1:10.
58.
Derynck R, Zhang Y, Feng XH: Smads: transcriptional activators of TGF-β responses. Cell 1998;95:737-740.
59.
Xia W, Voellmy R, Spector NL: Sensitization of tumor cells to Fas killing through overexpression of heat-shock transcription factor 1. J Cell Physiol 2000;183:425-431.
60.
Guo-Yan L, Qi L, Bin X, Chao P, Ping Y, Hong-Feng L, Wei-Chun Z, Hong-Zhi G: Tissue array for Tp53, C-myc, CCND1 gene over expression in different tumors. World J Gastroenterol 2008;14:7199-7207.
61.
Sutherland RL, Prall OW, Watts CK, Musgrove EA: Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 1998;3:63-72.
62.
Eeckhoute J, Caroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M: A cell-type specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Cancer Dev 2006;20:2513-2526.
63.
Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ: WISP-1 is a Wnt-1- and β-catenin responsive oncogene. Genes Dev 2000;14:585-595.
64.
Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, et al: WISP genes are members of the connective tissue factor family that are up-regulated in wnt-1 transformed cells and aberrantly expressed in human colon tumors. PNAS 1998;95:14717-14722.
65.
Fischer H, Salahshor S, Stenling R, Björk J, Lindmark G, Iselius L, Rubio C, Lindblom A: COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC Cancer 2001;1:17.
66.
Kim J, Zhang X, Rieger-Christ KM, Summerhayes IC, Wazer DE, Paulson KE, Yee AS: Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem 2006;281:10865-10875.
67.
Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al: MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011;334:252-255.
68.
Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA: MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2011;2:966-969.
69.
Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J: MED12 mutations in uterine fibroids - their relationship to cytogenetic subgroups. Int J Cancer 2012;131:1528-1536.
70.
Foster KG, Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010;285:14071-14077.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.